MediSense Ltd

What we do

MediSense makes a wearable patch for continuous physiological monitoring outside hospital. The device records single-lead ECG, respiration, temperature and activity for fourteen days on a single charge, streams to a clinician dashboard over the patient's phone, and applies on-device analysis so that only clinically meaningful events consume clinical attention. The product is used for arrhythmia detection, for post-discharge monitoring of heart failure patients, and increasingly in decentralised clinical trials.

Market and customers

Health systems everywhere are trying to move care out of hospital beds, and the constraint is rarely willingness — it is that discharging a patient who still needs observation requires something to observe them with. Our NHS customers buy through virtual ward and cardiology services, while our commercial pharmaceutical customers buy per patient per trial, at higher margin and with far shorter procurement cycles. Running both channels lets the trials business fund the longer health system sales cycle.

Traction

The device holds UKCA and CE marking as a Class IIa device. Over 11,000 patient monitoring episodes have been completed to date. Revenue in the last financial year was £1.4M, split roughly 60:40 between health system and trials customers. A service evaluation with a partner health board reported a 31% reduction in readmissions among monitored heart failure patients against a matched cohort, and that evaluation is now the anchor of our NHS sales case.

Team and investors

The company was founded by a University of Dundee sensor engineering group with a consultant cardiologist as clinical co-founder, and employs 24 people. Manufacturing is outsourced to a UK contract manufacturer under a validated process, which keeps the company's own capital requirement low. Prior funding includes seed rounds from two angel syndicates and Innovate UK grant support.

Current raise

A £2.5M Series A is being raised to fund FDA 510(k) clearance and US market entry, extend the wear duration to 28 days, and build the clinical evidence required for inclusion in national heart failure pathways.